Anti-Angiogenesis

Protein Licensed As Possible Gene Therapy Candidate To Prevent Blindness

Published in Gene Therapy Weekly, March 15th, 2001

An eye protein that blocks excessive blood vessel growth will be developed as a possible candidate for gene therapy to prevent blindness in individuals with macular degeneration and diabetic retinopathy.

The protein, pigment epithelium-derived factor, or PEDF, has been shown to halt angiogenesis in an animal model with an eye disease similar to human diabetes-related blindness.

Noel Bouck, professor of microbiology and immunology at the Northwestern University Medical School, Chicago, Illinois, who discovered the use of this protein in inhibiting angiogenesis, said PEDF may have important therapeutic implications in diabetic retinopathy and macular...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry